Davis Polk advised J.P. Morgan Securities LLC as sole underwriter in the SEC-registered offering by Insulet Corporation of $125 million aggregate principal amount of its 3.75% convertible senior notes due 2016, plus an $18.75 million over-allotment option, which has been exercised by the underwriter. Davis Polk also advised J.P. Morgan Securities LLC as representative of the several underwriters in the SEC-registered offering by Insulet’s selling stockholders of 1,153,420 shares of Insulet common stock. The selling stockholders received shares of Insulet in connection with Insulet’s recent acquisition of Neighborhood Diabetes, Inc., a medical equipment distributor specializing in direct to consumer sales of diabetes supplies. The common stock is listed on the Nasdaq Global Market under the symbol “PODD.”

Based in Bedford, Massachusetts, Insulet is a medical device company that develops and manufactures the OmniPod System, a discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Alan F. Denenberg, associates Jake S. Tyshow, Jeffrey Gould and Livingston A. Miller and summer associate Nicholas D. DiChiara. The tax team included partner Rachel D. Kleinberg and associate Catherine Paskoff Chang. The environmental team included counsel Betty Moy Huber and summer associate Branden C. Berns. Jack S. Keating was the legal assistant for the transactions. Members of the Davis Polk team are based in the New York and Menlo Park offices.